Dr. Hamlin on Next Steps With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

Paul A. Hamlin, MD
Published: Monday, Aug 21, 2017



Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

The initial experience as a phase I study has been encouraging, Hamlin explains, especially in the MCL cohort. These are patients with fairly aggressive disease and with blastic features whom experienced prominent responses to the therapy and were durable. It is likely that there will be more options in the future thats attack both processes, he adds.

Researchers already know that ibrutinib is effective as a single agent in MCL; therefore, attacking more than 1 pathway is what likely leads to the more durable responses, he concludes.


Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

The initial experience as a phase I study has been encouraging, Hamlin explains, especially in the MCL cohort. These are patients with fairly aggressive disease and with blastic features whom experienced prominent responses to the therapy and were durable. It is likely that there will be more options in the future thats attack both processes, he adds.

Researchers already know that ibrutinib is effective as a single agent in MCL; therefore, attacking more than 1 pathway is what likely leads to the more durable responses, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x